



## Restoring Ethical and Effective Communication about Vaccination

Guest Editors:

**Prof. Dr. Arri Eisen**

Department of Biology, Institute  
for the Liberal Arts, Emory  
University, Atlanta, GA 30322,  
USA

arri.eisen@emory.edu

**Dr. Odaro John Huckstep**

United States Air Force Academy,  
Colorado Springs, CO 80840, USA

odaro.huckstep@  
afacademy.af.edu

Deadline for manuscript  
submissions:

**1 June 2023**

### Message from the Guest Editors

Vaccination, a topic that had long been neglected in the broader public interest, found itself in the midst of a vigorous and polarized debate during the COVID-19 pandemic. Much emphasis has been placed on particular positions and policies regarding vaccination. However, as both the masses and health professionals deal with fatigue, frustration, and challenges to their trust, it is time to reemphasize *how* we communicate, as much or more than *what* we communicate. Time is of the essence, as there is an urgent need for a range of new vaccinations—there are already warnings of a ‘triple-demic’ of COVID-19, flu, and respiratory syncytial virus this year—which may become part of 21st century life and beyond. Similarly, we must restore focus and momentum on vaccine development against globally important diseases such as malaria and viral hemorrhagic fevers. In this Special Issue, we invite data, insights, exploration, and reflection from across biomedical, social science, and humanities disciplines on this ethical imperative—to restore trust and, with it, health.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:**— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPlus / SciFinder](#), and [other databases](#).

**Journal Rank:** [JCR - Q2 \(Immunology\)](#) / [CiteScore - Q2 \(Pharmacology \(medical\)\)](#)

## Contact Us

---

*Vaccines*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)